Skip to main content
Indian stocks: Visit www.stage2stocks.com →

10x Genomics, Inc.

Stage 2 · Advancing · week 48

As of Oct 22, 2026, 10x Genomics is in Stage 2, the uptrend phase, now in week 48 (since Nov 12, 2025). It closed at $69.75, 28.6% below its 52-week high and above its 200-day average, which is rising.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and th… More about the company

$69.75
-7.25% today
$9.1B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is TXG early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 26w
S4 34w
S2 49w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 1w → S3 6w → S4 10w → S1 11w → S4 26w → S1 7w → S4 34w → S1 8w → S2 8w → S3 5w → S2 49w current
Total tracked: 166 weeks across 11 stage runs.

TXG among Medical Devices1st of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
vs 52W High
-28.6%
$12.26 lo$97.74 hi
28.6% below 52W high, far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 48
1w13w26w
Week 48, mature
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
79.4%
200 DMA: $38.89 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.24x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-7.8%
3M
+50.7%
6M
+225.6%
YTD
+319.7%
1Y
+435.3%
Scan Membership
Breakout Watch
Latest: 2023-02-03
4 appearances in last 60 days. First seen: 2020-06-26.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 48 · Vol 1.24x
2026-10-21S2
Wk 48 · Vol 0.91x
2026-10-20S2
Wk 47 · Vol 0.82x
2026-10-19S2
Wk 47 · Vol 0.72x
2026-10-16S2
Wk 47 · Vol 0.96x
2026-10-15S2
Wk 47 · Vol 1.24x
2026-10-14S2
Wk 47 · Vol 1.20x
2026-10-13S2
Wk 46 · Vol 1.18x
2026-10-12S2
Wk 46 · Vol 1.20x
2026-10-09S2
Wk 46 · Vol 1.09x
2026-10-08S2
Wk 46 · Vol 1.72x
2026-10-07S2
Wk 46 · Vol 2.95x
Moving averages & range
50 DMA
$72.08
200 DMA
$38.89
52W High
$97.74
52W Low
$12.26
5D Low
$69.75
Resistance levels (recent highs)
20d High
$97.74
60d High
$97.74
120d High
$97.74
250d High
$97.74
Next resistance
+40.1%
to 20d High
ROE
-9.4%
Profit margin -12.2%
Dividend Yield
0.00%
P/B 11.0

10x Genomics: quick answers

What stage is 10x Genomics in?

As of Oct 22, 2026, 10x Genomics (TXG) is in Stage 2, the uptrend phase. It entered Stage 2 on Nov 12, 2025 and is in week 48. What the four stages mean

Is 10x Genomics in an uptrend?

Yes. 10x Genomics is in a Stage 2 uptrend. It trades 79.4% above its 200-day average, which is rising.

How far is 10x Genomics from its 52-week high?

10x Genomics closed at $69.75 on Oct 22, 2026, 28.6% below its 52-week high of $97.74. Its 52-week low is $12.26.

How has 10x Genomics performed over the past year?

As of Oct 22, 2026, 10x Genomics is up 435.3% over the past year and up 319.7% so far in 2026.

Which sector and industry is 10x Genomics in?

10x Genomics is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.